The Division of Gynecologic Oncology has one of the largest Clinical Trial Research Programs in Northern California and is on the forefront of translational research in gynecologic cancers. Through the collaborative work of our providers, research team and other UCSF staff, we offer a wide variety of clinical trials that provide women with gynecologic cancers access to cutting edge investigational therapies and treatment methods. Our practice serves as a regional research hub which attracts patients from across California seeking out clinical trials. Additionally, we are a voting member of the national Cooperative Group NRG Oncology, an interdisciplinary research organization dedicated to improving the survival and quality of life of cancer patients through research, where we help to shape Gynecologic Oncology care on a national and global level. We are excited to continue to grow our Clinical Research Program by adding additional staff and expanding our trial portfolio, with the goal of being able to provide any woman with gynecologic cancer interested in participating in a clinical trial access to potentially life-saving therapy.
ARIEL 2: CO-338-017: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - https://clinicaltrials.gov/ct2/show/NCT01891344
ARIEL 3: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer - https://clinicaltrials.gov/ct2/show/NCT01968213
AZD1775 GYN49: A Study of AZD1775 + Chemotherapy Versus Chemotherapy in Patients to Treat Ovarian, Fallopian Tube, Peritoneal Cancer - https://clinicaltrials.gov/ct2/show/NCT02272790
PLX3397: A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer - https://clinicaltrials.gov/ct2/show/NCT01525602
NRG (GOG) Cooperative Group Trials
GOG 283: A Phase II Trial of DTTD-Sponsored Dasatinib (NSC #73517 IND # 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
GOG 277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) followed by Doxorubicin (NSC# 123127) v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma (NCT# 01533207)
GOG 265: A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND #13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix (Currently on hold for interim data analysis)
GOG 281: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (NCT02101788) (Currently on hold)
GOG 286B A Randomized Phase II/III study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as initial therapy for measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (NCT02065687) (Temporarily closed to accrual)
GOG 3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02470585 (Est. April 2016)
If you would like more information regarding our Gynecologic Oncology Trials at UCSF, please email our team at GynOncClinicalTrials@UCSF.edu.